Literature DB >> 25120128

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.

Stephen M Hatfield1, Jorgen Kjaergaard, Dmitriy Lukashev, Bryan Belikoff, Taylor H Schreiber, Shalini Sethumadhavan, Robert Abbott, Phaethon Philbrook, Molly Thayer, Dai Shujia, Scott Rodig, Jeffrey L Kutok, Jin Ren, Akio Ohta, Eckhard R Podack, Barry Karger, Edwin K Jackson, Michail Sitkovsky.   

Abstract

UNLABELLED: Intratumoral hypoxia and hypoxia inducible factor-1α (HIF-1-α)-dependent CD39/CD73 ectoenzymes may govern the accumulation of tumor-protecting extracellular adenosine and signaling through A2A adenosine receptors (A2AR) in tumor microenvironments (TME). Here, we explored the conceptually novel motivation to use supplemental oxygen as a treatment to inhibit the hypoxia/HIF-1α-CD39/CD73-driven accumulation of extracellular adenosine in the TME in order to weaken the tumor protection. We report that hyperoxic breathing (60 % O2) decreased the TME hypoxia, as well as levels of HIF-1α and downstream target proteins of HIF-1α in the TME according to proteomic studies in mice. Importantly, oxygenation also downregulated the expression of adenosine-generating ectoenzymes and significantly lowered levels of tumor-protecting extracellular adenosine in the TME. Using supplemental oxygen as a tool in studies of the TME, we also identified FHL-1 as a potentially useful marker for the conversion of hypoxic into normoxic TME. Hyperoxic breathing resulted in the upregulation of antigen-presenting MHC class I molecules on tumor cells and in the better recognition and increased susceptibility to killing by tumor-reactive cytotoxic T cells. Therapeutic breathing of 60 % oxygen resulted in the significant inhibition of growth of established B16.F10 melanoma tumors and prolonged survival of mice. Taken together, the data presented here provide proof-of principle for the therapeutic potential of systemic oxygenation to convert the hypoxic, adenosine-rich and tumor-protecting TME into a normoxic and extracellular adenosine-poor TME that, in turn, may facilitate tumor regression. We propose to explore the combination of supplemental oxygen with existing immunotherapies of cancer. KEY MESSAGES: Oxygenation decreases levels of tumor protecting hypoxia. Oxygenation decreases levels of tumor protecting extracellular adenosine. Oxygenation decreases expression of HIF-1alpha dependent tumor-protecting proteins. Oxygenation increases MHC class I expression and enables tumor regression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25120128      PMCID: PMC4247798          DOI: 10.1007/s00109-014-1189-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 2.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  Four-and-a-half LIM domain proteins inhibit transactivation by hypoxia-inducible factor 1.

Authors:  Maimon E Hubbi; Daniele M Gilkes; Jin H Baek; Gregg L Semenza
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

5.  Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung.

Authors:  N C Margaretten; H Witschi
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

6.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

7.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

Authors:  Lili Feng; Xiaofeng Sun; Eva Csizmadia; Lihui Han; Shu Bian; Takashi Murakami; Xin Wang; Simon C Robson; Yan Wu
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

8.  Macrophage A2A adenosinergic receptor modulates oxygen-induced augmentation of murine lung injury.

Authors:  Neil R Aggarwal; Franco R D'Alessio; Yoshiki Eto; Eric Chau; Claudia Avalos; Adam T Waickman; Brian T Garibaldi; Jason R Mock; Daniel C Files; Venkataramana Sidhaye; Vsevolod Y Polotsky; Jonathan Powell; Maureen Horton; Landon S King
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 9.  Regulation of cyclooxygenase-2 expression by cyclic AMP.

Authors:  Thomas Klein; Pierre Shephard; Hartmut Kleinert; Martin Kömhoff
Journal:  Biochim Biophys Acta       Date:  2007-09-12

10.  Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury.

Authors:  Manfred Thiel; Alexander Chouker; Akio Ohta; Edward Jackson; Charles Caldwell; Patrick Smith; Dmitry Lukashev; Iris Bittmann; Michail V Sitkovsky
Journal:  PLoS Biol       Date:  2005-05-03       Impact factor: 8.029

View more
  72 in total

1.  Can respiratory hyperoxia mitigate adenosine-driven suppression of antitumor immunity?

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Ann Transl Med       Date:  2015-11

Review 2.  Role of hyperoxic treatment in cancer.

Authors:  Sei W Kim; In K Kim; Sang H Lee
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-23

3.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

Review 4.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

5.  The GS Protein-coupled A2a Adenosine Receptor Controls T Cell Help in the Germinal Center.

Authors:  Robert K Abbott; Murillo Silva; Jasmine Labuda; Molly Thayer; Derek W Cain; Phaethon Philbrook; Shalini Sethumadhavan; Stephen Hatfield; Akio Ohta; Michail Sitkovsky
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

Review 6.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

7.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Authors:  Debangshu Samanta; Youngrok Park; Xuhao Ni; Huili Li; Cynthia A Zahnow; Edward Gabrielson; Fan Pan; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-24       Impact factor: 11.205

8.  Loss of CD73-mediated extracellular adenosine production exacerbates inflammation and abnormal alveolar development in newborn mice exposed to prolonged hyperoxia.

Authors:  Huiling Li; Harry Karmouty-Quintana; Ning-Yuan Chen; Tingting Mills; Jose Molina; Michael R Blackburn; Jonathan Davies
Journal:  Pediatr Res       Date:  2017-08-23       Impact factor: 3.756

9.  Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils.

Authors:  Karim Mahiddine; Adam Blaisdell; Stephany Ma; Amandine Créquer-Grandhomme; Clifford A Lowell; Adrian Erlebacher
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

10.  Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Authors:  Xichen Zheng; Zhaoxu Fang; Xiaomei Liu; Shengming Deng; Pei Zhou; Xuexiang Wang; Chenglin Zhang; Rongping Yin; Haitian Hu; Xiaolan Chen; Yijie Han; Yun Zhao; Steven H Lin; Songbing Qin; Xiaohua Wang; Betty Ys Kim; Penghui Zhou; Wen Jiang; Qingyu Wu; Yuhui Huang
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.